The key question of this study is “what is the optimal first‐line therapy for driver gene‐negative NSCLC with brain metastases (BM), and can PD‐L1 predict intracranial efficacy?” This is a retrospective analysis of 36 patients treated with immune checkpoint inhibitor (ICI) + chemotherapy (CT) (n = 21) and ICI + CT + bevacizumab (Bev) (n = 15). The gene discussed is CD274; the disease is non-small cell lung carcinoma.